Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) shares, rose in value on Wednesday, 05/24/23, with the stock price down by -5.07% to the previous day’s close as strong demand from buyers drove the stock to $8.99.
Actively observing the price movement in the last trading, the stock closed the session at $9.47, falling within a range of $8.87 and $9.39. The value of beta (5-year monthly) was 0.46. Referring to stock’s 52-week performance, its high was $27.40, and the low was $9.23. On the whole, ARQT has fluctuated by -32.76% over the past month.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
With the market capitalization of Arcutis Biotherapeutics Inc. currently standing at about $551.00 million, investors are eagerly awaiting this quarter’s results, scheduled for Aug 02, 2023 – Aug 07, 2023. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$1.24, which is expected to increase to -$1.12 for fiscal year -$4.87 and then to about -$3.69 by fiscal year 2024. Data indicates that the EPS growth is expected to be 14.00% in 2024, while the next year’s EPS growth is forecast to be 24.20%.
Analysts have estimated the company’s revenue for the quarter at $5.31 million, with a low estimate of $4.6 million and a high estimate of $6.7 million. Wall Street analysts also predicted that in 2024, the company’s y-o-y revenues would reach $31.48 million, representing an increase of 754.00% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that ARQT’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
9 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 0 analyst(s), 9 recommend it as a Buy and 0 called the ARQT stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of ARQT currently trading nearly -26.52% and -25.71% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 29.03, while the 7-day volatility ratio is showing 5.72% which for the 30-day chart, stands at 7.34%. Furthermore, Arcutis Biotherapeutics Inc. (ARQT)’s beta value is 0.51, and its average true range (ATR) is 0.81. The company’s stock has been forecasted to trade at an average price of $45.33 over the course of the next 52 weeks, with a low of $24.00 and a high of $65.00. Based on these price targets, the low is -166.96% off current price, whereas the price has to move -623.03% to reach the yearly target high. Additionally, analysts’ median price of $45.00 is likely to be welcomed by investors because it represents a decrease of -400.56% from the current levels.
A comparison of Arcutis Biotherapeutics Inc. (ARQT) with its peers suggests the former has fared considerably weaker in the market. ARQT showed an intraday change of -5.07% in last session, and over the past year, it shrunk by -57.83%%. In comparison, Eli Lilly and Company (LLY) has moved higher at 0.60% on the day and was up 40.70% over the past 12 months. On the other hand, the price of AbbVie Inc. (ABBV) has fallen -0.96% on the day. The stock, however, is off -4.65% from where it was a year ago. Additionally, there is a loss of -2.55% for Pfizer Inc. (PFE) in last trading while the stock has seen an overall depriciation of -26.95%% over the past year. Other than that, the overall performance of the S&P 500 during the last trading session shows that it lost -0.73%. Meanwhile, the Dow Jones Industrial Slipped by -0.77%.
Data on historical trading for Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) indicates that the trading volumes over the past 10 days have averaged 1.48 million and over the past 3 months, they’ve averaged 1.17 million. According to company’s latest data on outstanding shares, there are 61.17 million shares outstanding.
Nearly 1.40% of Arcutis Biotherapeutics Inc.’s shares belong to company insiders and institutional investors own 98.40% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 15.39 million shares as on Apr 27, 2023, resulting in a short ratio of 15.31. According to the data, the short interest in Arcutis Biotherapeutics Inc. (ARQT) stood at 25.09% of shares outstanding as of Apr 27, 2023; the number of short shares registered in Mar 30, 2023 reached 15.12 million. The stock has fallen by -39.26% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ARQT stock heading into the next quarter.